Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.

Oguejiofor, Kenneth K; Galletta-Williams, Henry; Dovedi, Simon J; Roberts, Darren L; Stern, Peter L; West, Catharine M L

dc.contributor.author	Oguejiofor, Kenneth K
dc.contributor.author	Galletta-Williams, Henry
dc.contributor.author	Dovedi, Simon J
dc.contributor.author	Roberts, Darren L
dc.contributor.author	Stern, Peter L
dc.contributor.author	West, Catharine M L
dc.date.accessioned	2017-02-24T09:30:28Z
dc.date.available	2017-02-24T09:30:28Z
dc.date.issued	2017-01-22
dc.identifier.citation	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. 2017, Oncotarget	en
dc.identifier.issn	1949-2553
dc.identifier.pmid	28122336
dc.identifier.doi	10.18632/oncotarget.14796
dc.identifier.uri	http://hdl.handle.net/10541/620158
dc.description.abstract	Immunotherapies are beginning to revolutionise treatment paradigms in oncology with monoclonal antibodies (mAb) targeting T-cell co-inhibitory (e.g. PD-1/PD-L1) and co-stimulatory pathways (e.g. CTLA-4/CD28) demonstrating clinical utility. Some clinical studies demonstrate that responsiveness to PD-1/PD-L1 mAb therapy is greater in patients with expression of PD-L1 in the tumour microenvironment. However, robust responses have also been observed in patients with low or absent expression of PD-L1. Using multiplex immuno-fluorescent labelling we sought to determine how infiltration of tumours by CD8+ T-cells, their expression of PD-1, and the expression of PD-L1 on both tumours and CD68 cells (macrophages) correlated with HPV status and outcome in a cohort of 124 oropharyngeal squamous cell carcinomas (OPSCC).
dc.language.iso	en	en
dc.rights	Archived with thanks to Oncotarget	en
dc.title	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.	en
dc.type	Article	en
dc.contributor.department	Translational Radiobiology Group, Division of Molecular & Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital NHS Trust, Manchester	en
dc.identifier.journal	Oncotarget	en
refterms.dateFOA	2018-12-17T14:48:09Z
html.description.abstract	Immunotherapies are beginning to revolutionise treatment paradigms in oncology with monoclonal antibodies (mAb) targeting T-cell co-inhibitory (e.g. PD-1/PD-L1) and co-stimulatory pathways (e.g. CTLA-4/CD28) demonstrating clinical utility. Some clinical studies demonstrate that responsiveness to PD-1/PD-L1 mAb therapy is greater in patients with expression of PD-L1 in the tumour microenvironment. However, robust responses have also been observed in patients with low or absent expression of PD-L1. Using multiplex immuno-fluorescent labelling we sought to determine how infiltration of tumours by CD8+ T-cells, their expression of PD-1, and the expression of PD-L1 on both tumours and CD68 cells (macrophages) correlated with HPV status and outcome in a cohort of 124 oropharyngeal squamous cell carcinomas (OPSCC).